Brief: Orchard Therapeutics Announces Clinical Proof-Of-Concept Data For Gene Therapy OTL-300
29/04/2019 12:18
April 29 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES CLINICAL PROOF-OF-CONCEPT
DATA
FOR GENE THERAPY OTL-300 DEMONSTRATING EFFICACY IN
TRANSFUSION-DEPENDENT BETA-THALASSEMIA
* ORCHARD THERAPEUTICS PLC - PRESENTATION OF FULL CLINICAL
PROOF-OF-CONCEPT DATA FROM ITS TRIAL OF EX VIVO, AUTOLOGOUS, HSC
GENE THERAPY, OTL-300,
Source text for Eikon: ID:nGNX8BxKSS
Further company coverage: ORTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln